title: Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Sanam
authors.identifier: http://orcid.org/0000-0001-8980-3202
authors.initials: S
authors.lastname: Loghavi
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Naveen
authors.initials: N
authors.lastname: Pemmaraju
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Rashmi
authors.identifier: http://orcid.org/0000-0001-7829-5249
authors.initials: R
authors.lastname: Kanagal-Shamanna
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Meenakshi
authors.identifier: http://orcid.org/0000-0001-8787-4082
authors.initials: M
authors.lastname: Mehrotra
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: L Jeffrey
authors.identifier: http://orcid.org/0000-0001-6577-8006
authors.initials: LJ
authors.lastname: Medeiros
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Raja
authors.initials: R
authors.lastname: Luthra
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Pei
authors.initials: P
authors.lastname: Lin
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Yang
authors.identifier: http://orcid.org/0000-0002-6321-1476
authors.initials: Y
authors.lastname: Huh
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.affiliation: Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, TX.
authors.forename: Keyur P
authors.initials: KP
authors.lastname: Patel
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D037282:Calreticulin / Q000235:genetics*; D000069439:Dasatinib; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D037282:Calreticulin; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib